Skip to content Skip to navigation

Announcement:

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Announcement:

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma

Flagship Pioneering

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

LinkedIn
X
YouTube

Media Highlights

Flagship Pioneering debuts new startup using AI to design disease-fighting proteins

Fierce Biotech 09.11.2020

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

Now we can.

Generate:Biomedicines
101 South Street, Suite 900
Somerville, MA 02143
United States

© 2026 Generate:Biomedicines

LinkedIn
X
YouTube

Privacy Policy Terms of Use Cookie Settings